Dengue Author: Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath; Panduka Karunanayake, MD, MRCP; Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP
Editorial changes - 2009-11-13
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Follow-up

Discharge patients at the appropriate time, and arrange follow-up to look for disease sequelae.C

  • Discharge patients when the following criteria are met:
    • Absence of fever for at least 24 hours without the use of antipyretics
    • A minimum of 3 days after recovery from dengue shock syndrome with stable pulse, blood pressure, and respiratory rate
    • No respiratory distress from a pleural effusion and no ascites
    • No evidence of internal or external bleeding
    • Good urinary output and stable hematocrit
    • Platelet count >50 × 109/L, if the count is increasing
    • Presence of a convalescent confluent rash
  • At follow-up visits, ask about:
    • Anorexia
    • Joint and muscle pain
    • Fatigue and depression
    • Bleeding manifestations
  • At follow-up visits, examine the patient for:
    • Bleeding manifestations
    • Hepatomegaly
  • Provide general advice and treatment of symptoms as needed for any persistent clinical manifestations, such as fatigue, after recovery from the acute illness.
  • See table Elements of Follow-up for Dengue.
Background

FAQs
Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Panduka Karunanayake, MD, MRCP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.